Indaptus Therapeutics, Inc. — Form SCHEDULE 13D/A
Filed October 22, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
SINO LION VENTURES Ltd filed an amended Schedule 13D/A on October 22, 2026, regarding beneficial ownership in Indaptus Therapeutics, Inc. (public market value ~$5.8M). The filing document itself contains no specific share counts, percentages, dollar amounts, or details of what changed from the prior Schedule 13D. The amendment's substance cannot be determined from the header information provided.
Why this rating
Amendment filing is routine disclosure with no disclosed material change quantified. Cannot assess impact without actual ownership percentages or share data.
See more from October 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.